Baseline and Kinetic Circulating Tumor Cell Counts Are Prognostic Factors in a Prospective Study of Metastatic Colorectal Cancer

Autor(es)

Souza e Silva, Virgilio ^[1] ; Abdallah, Emne Ali ^[2] ; Carvalho de Brito, Angelo Borsarelli ^[1] ; Braun, Alexcia Camila ^[2] ; Tariki, Milena Shizue ^[1] ; Lopes de Mello, Celso Abdon ^[1] ; Calsavara, Vinicius Fernando ^[2] ; Riechelmann, Rachel ^[1] ; Domingos Chinen, Ludmilla Thome ^[2]

Afiliação do(s) autor(es)

^[1] AC Camargo Canc Ctr, Dept Med Oncol, BR-01509900 Sao Paulo - Brazil

^[2] AC Camargo Canc Ctr, Int Res Ctr, BR-01508010 Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: DIAGNOSTICS; v. 11, n. 3 MAR 2021.
• Citações Web of Science: 0

Resumo

The discovery of predictive biomarkers in metastatic colorectal cancer (mCRC) is essential to improve clinical outcomes. Recent data suggest a potential role of circulating tumor cells (CTCs) as prognostic indicators. We conducted a follow-on analysis from a prospective study of consecutive patients with mCRC. CTC analysis was conducted at two timepoints: baseline (CTC1; before starting chemotherapy), and two months after starting treatment (CTC2). CTC isolation/quantification were completed by ISET(R) (Rarecells, France). CTC expressions of drug resistance-associated proteins were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Seventy-five patients were enrolled from May 2012 to May 2014. A CTC1 cut-off of >1.5 CTCs/mL was associated with an inferior median OS compared to lower values. A difference of CTC2-CTC1 > 5.5 CTCs/mL was associated with a reduced median PFS. By multivariate analysis, CTC1 > 1.5 CTCs/mL was an independent prognostic factor for worse OS. Multi-drug resistance protein-1 (MRP-1) expression was associated with poor median OS. CTC baseline counts, kinetics, and MRP-1 expression were predictive of clinical outcomes. Larger studies are warranted to explore the potential clinical benefit of treating mCRC patients with targeted therapeutic regimens guided by CTC findings. (AU)

• Processo FAPESP: 12/01273-8 - Detecção de células tumorais circulantes e sua correlação com evolução clínica tumoral
• Beneficiário: Fernando Augusto Soares
• Modalidade de apoio: Auxílio à Pesquisa - Regular